Literature DB >> 25498414

Dopamine D3 receptor agonists as pharmacological tools.

S Kassel1, J S Schwed1, H Stark2.   

Abstract

Dysregulation of the dopaminergic innervation in the central nervous system plays a key role in different neurological disorders like Parkinson´s disease, restless legs syndrome, schizophrenia etc. Although dopamine D3 receptors have been recognized as an important target in these diseases, their full pharmacological properties need further investigations. With focus on dopamine D3 receptor full agonists, this review has divided the ergoline and non-ergoline ligands in dissimilar chemical subclasses describing their pharmacodynamic properties on different related receptors, on species differences and their functional properties on different signaling mechanism. This is combined with a short description of structure-activity relationships for each class. Therefore, this overview should support the rational choice for the optimal compound selection based on affinity, selectivity and efficacy data in biochemical and pharmacological studies.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Affinity; Dopamine D(3) receptor; Efficacy; GPCR; Pharmacophore; Selectivity

Mesh:

Substances:

Year:  2014        PMID: 25498414     DOI: 10.1016/j.euroneuro.2014.11.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  4 in total

1.  Hydroxysafflor Yellow A Improves Motor Dysfunction in the Rotenone-Induced Mice Model of Parkinson's Disease.

Authors:  Tian Wang; Lijie Wang; Cuiting Li; Bing Han; Zhenhua Wang; Ji Li; Yan Lv; Shuyun Wang; Fenghua Fu
Journal:  Neurochem Res       Date:  2017-01-17       Impact factor: 3.996

Review 2.  Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.

Authors:  Samuele Maramai; Sandra Gemma; Simone Brogi; Giuseppe Campiani; Stefania Butini; Holger Stark; Margherita Brindisi
Journal:  Front Neurosci       Date:  2016-10-05       Impact factor: 4.677

Review 3.  Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.

Authors:  Béla Kiss; István Laszlovszky; Balázs Krámos; András Visegrády; Amrita Bobok; György Lévay; Balázs Lendvai; Viktor Román
Journal:  Biomolecules       Date:  2021-01-14

Review 4.  Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo.

Authors:  Béla Kiss; Balázs Krámos; István Laszlovszky
Journal:  Front Psychiatry       Date:  2022-03-24       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.